Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2658 - The prognostic value of the Modified Glasgow Prognostic Score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Translational Research

Tumour Site

Pancreatic Adenocarcinoma


Li-Tzong Chen


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


L. Chen1, T.M. Macarulla2, B. Belanger3, B. Mirakhur4, F.A. de Jong5, J. Siveke6

Author affiliations

  • 1 Internal Medicine, National Health Research Institutes – National Institute of Cancer Research, 350 - Tainan/TW
  • 2 Vall D'hebron Institute Of Oncology (vhio), Vall d'Hebron University Hospital (HUVH), Barcelona/ES
  • 3 Biometry R&d, Ipsen Biopharmaceuticals,Inc., Cambridge/US
  • 4 Medical Affairs, Ipsen Biopharmaceuticals,Inc., Basking Ridge/US
  • 5 Medical Affairs, Shire GmbH, ZUG/CH
  • 6 Division Of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2658


mGPS has been identified as a prognostic factor of OS in patients with pancreatic cancer. Here we report the association between mGPS and OS in a post-hoc analysis of the NAPOLI-1 study (NCT01494506), which demonstrated improved survival for nal-IRI+5-FU/LV vs 5-FU/LV in the treatment of patients with mPDAC previously treated with gemcitabine-based therapy.


All patients treated in the NAPOLI-1 study with available baseline plasma Creactive protein (CRP) and albumin data (data cutoff: Nov 16, 2015) were included in this post-hoc analysis. Eligible patients were stratified by mGPS (mGPS-0: CRP ≤10 mg/L regardless of albumin level; mGPS-1: CRP >10 mg/L, albumin ≥35 g/L; and mGPS-2: CRP >10 mg/L, albumin <35 g/L). OS was assessed in individual and pooled treatment arms. A stepwise Cox regression model of OS was used to evaluate the prognostic significance of mGPS.


Baseline plasma C-reactive protein and albumin data was available for N = 184 patients: mGPS-0, n = 79; mGPS-1, n = 88; mGPS-2, n = 17. For patients in pooled treatment arms, median OS was worse for the mGPS-1 group than for the mGPS-0 group (4.0 vs 8.0 months, respectively), but was comparable between the mGPS-2 and mGPS-1 groups (3.2 vs 4.0 months, respectively). Multivariate analysis revealed both mGPS-1 and mGPS-2 were independent predictive factors of death (mGPS-1: HR, 3.34; 95% CI, 2.25–4.95, P < 0.0001; mGPS-2: HR, 5.89; 95% CI, 3.21–10.80, P < 0.001). Similarly, analysis by treatment arm showed OS of patients treated with nal-IRI+5-FU/LV was significantly worse in the mGPS-1 (N = 26) and mGPS-2 (N = 5) groups than in the mGPS-0 (N = 27) group (4.6, 3.3 vs 9.3 months, respectively)


Data from this post-hoc analyses of mGPS in patients with mPDAC previously treated with gemcitabine-based are consistent with the reports of the prognostic value of the mGPS in estimating OS. Median OS was significantly improved in pts with a mGPS-0 vs mGPS-1 or mGPS-2, including the treatment group of patients receiving nal-IRI+5-FU/LV.

Clinical trial identification


Legal entity responsible for the study

Ipsen Biopharmaceuticals, Inc.


Ipsen Biopharmaceuticals, Inc.

Editorial Acknowledgement

Editorial assistance was provided by The Medicine Group (New Hope, PA, USA); Philip Sjostedt, BPharm; Susan Martin, PhD.


L-T. Chen: Consulting or advisory role: Bristol-Myers Squibb, Five Prime Therapeutics, Lilly, Merrimack, MSD, Novartis, Ono Pharmaceutical, PharmaEngine, Syncope, Taiwan, TTY Biopharm; Research funding (Inst): GlaxoSmithKline, Merck Serono, Novartis, Polaris, TTY Biopharm; Patents, Royalties, Other intellectual property: Anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan. B. Belanger, B. Mirakhur: Employee stock, Other ownership interests: Ipsen Biopharmaceuticals, Inc. F.A. de Jong: Employee: Shire Stock, Other ownership interests: Amgen, Shire. J. Siveke: Consulting, Advisory role: Baxalta, Celgene, Lilly, Merrimack; Research funding: 4SC; Boehringer Ingelheim, Bristol-Myers Squibb, Celgene;, Novartis, Travel, accommodations, expensive: Celgene, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.